2[1]Bone RC,BalK RA,Cerra FB,et al.The ACCP/SCCM Consensus Conference Committee.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J].Chest,1992,101:1644-55.
3[2]Ronce C,Bellomo R.Continuous renal replacement therapy:Evolution in technology and current nomenclature[J].Kidney Int,1998,53(S66):160-6.
5[4]Giovanni Camussi,Claudio Ronco,Giuseppe Montrucchio,et al.Role of soluble mediators in sepsis and renal failure[J].Kidney Int,1998,53(S66):79-83.
6[5]Selzman CH,Shames BD,Miller SA,et al.Therapeutic implications of interleukin-10 in surgical diseases[J].Shock,1998,10:309-18.
7[6]Van Bommel EF,Hesse CJ,Jutte NH,et al.Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome[J].Ren Fail,1997,19:443-54.
8[7]Vrise,Colarayn FA,Philippe JJ.Cytokine removal during continuous hemofiltration in septic patients[J].J Am Soc Nephrol,1999,10:846-9.
9[8]Lonnemann G,Schindler R,Dinarello C,et al.Removal of circulating cytokines by hemodialysis membranes in vitro,in host defense dysfunction in trauma,shock and sepisis[J].Springer Verlag,1993,12:613-8.
